Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Large Decline in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant decline in short interest in May. As of May 29th, there was short interest totaling 17,200 shares, a decline of 71.4% from the May 14th total of 60,118 shares. Based on an average daily volume of 132,680 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Indaptus Therapeutics Trading Up 44.5%

NASDAQ INDP traded up $1.09 on Thursday, reaching $3.54. 3,272,764 shares of the company were exchanged, compared to its average volume of 560,439. The business’s fifty day moving average price is $2.19 and its 200 day moving average price is $2.21. The stock has a market capitalization of $400.98 million, a P/E ratio of -0.23 and a beta of 1.25. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $19.91.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors own 7.06% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Indaptus Therapeutics presently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.